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ARTICLE OPEN
Safety and efﬁcacy of tiotropium Respimat versus
HandiHaler in patients naive to treatment with inhaled
anticholinergics: a post hoc analysis of the TIOSPIR trial
Robert Wise1, Peter MA Calverley2, Ronald Dahl3, Daniel Dusser4, Norbert Metzdorf5, Achim Müller6, Andy Fowler7 and
Antonio Anzueto8
BACKGROUND: Patients with chronic obstructive pulmonary disease (COPD) who were naive to anticholinergics before the
TIOtropium Safety and Performance In Respimat (TIOSPIR) trial may reﬂect patients seen in practice, in particular in primary care. In
addition, investigating safety in these patients avoids the potential bias in patients who previously received anticholinergics and
may be tolerant of their effects.
AIMS: The aim of this study was to evaluate whether patients naive to anticholinergic therapy who were treated with tiotropium
Respimat 2.5 or 5 μg had different safety and efﬁcacy outcomes than patients treated with tiotropium HandiHaler 18 μg.
METHODS: A post hoc analysis of patients who were not receiving anticholinergics before TIOSPIR (N= 6,966/17,135) was
conducted. Primary end points were risk of death from any cause and risk of COPD exacerbation. Secondary outcomes included
severe exacerbation and major adverse cardiovascular events (MACE). Additional analysis of exacerbations was carried out in
anticholinergic-naive patients with moderate (GOLD II) disease.
RESULTS: Anticholinergic-naive patients had less severe disease than the total TIOSPIR population. Discontinuations because of
anticholinergic side effects were infrequent (0.9% overall). Similar to the primary study, patients in the tiotropium Respimat groups
had no difference in the risk of death or risk of any or severe exacerbation than patients treated with tiotropium HandiHaler. Risk of
MACE was similar across the Respimat and HandiHaler groups. Rates of exacerbations in the subgroup of patients with moderate
disease were similar across the Respimat and HandiHaler groups.
CONCLUSIONS: Tiotropium Respimat and HandiHaler have similar safety and efﬁcacy proﬁles in patients who are naive to
anticholinergic therapy.
npj Primary Care Respiratory Medicine (2015) 25, 15067; doi:10.1038/npjpcrm.2015.67; published online 5 November 2015
INTRODUCTION
Tiotropium (SPIRIVA, Boehringer Ingelheim Pharma & Co KG,
Ingelheim am Rhein, Germany) is a once-daily, long-acting,
anticholinergic bronchodilator available in two formulations: dry
powder via HandiHaler (18 μg once daily) and as an aqueous
solution via the Respimat Soft Mist Inhaler (5 μg (two puffs of
2.5 μg once daily)).1,2 Tiotropium HandiHaler 18 μg and tiotropium
Respimat 5 μg have demonstrated similar improvements in lung
function, symptoms and quality of life3–6 and have similar
pharmacokinetic proﬁles in patients with chronic obstructive
pulmonary disease (COPD).7
Queries around the safety of Respimat8–10 were addressed in the
TIOtropium Safety and Performance In Respimat (TIOSPIR;
NCT01126437) trial11—the largest long-term, randomised, double-
blind trial in patients with COPD performed to date. The trial showed
similar safety and exacerbation efﬁcacy proﬁles for tiotropium
Respimat 2.5 μg and 5 μg compared with HandiHaler 18 μg.
A common criticism of randomised clinical trials (RCTs) is that
the selected patient populations may not be truly representative
of patients seen in routine clinical practice—in particular, patients
treated in primary care.12–14 A unique characteristic of TIOSPIR was
the liberal inclusion criteria that were chosen to select a typical
COPD patient population, including patients with a wide range of
disease severities, as well as patients with stable cardiac disease.11
TIOSPIR also included a large population of patients with COPD
who were naive to anticholinergic treatment at baseline. This
represents an important patient group that may be highly
representative of patients commonly seen in primary care.
Patients within the primary TIOSPIR study who were previously
treated with anticholinergics might be seen to constitute a
selected population with a higher tolerance to anticholinergic
effects and could have introduced a selection bias in the analysis
of tiotropium’s safety. Therefore, it is conceivable that the
anticholinergic-naive group might have been at an increased risk
of side effects commonly associated with the class and may have
responded differently to treatment with tiotropium Respimat or
HandiHaler.
To investigate this possibility, this post hoc analysis of the
TIOSPIR trial studied whether patients who had not previously
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received anticholinergic therapy and who were treated with
Respimat 2.5 or 5 μg had different safety and/or efﬁcacy outcomes
compared with patients treated with HandiHaler 18 μg.
MATERIALS AND METHODS
Study design
TIOSPIR was a large (N= 17,135) long-term (2–3 years), randomised,
double-blind, double-dummy, parallel-group, actively controlled, event-
driven trial in patients with COPD.11,15 Patients received once-daily
Respimat 2.5 μg (two puffs of 1.25 μg) or 5 μg (two puffs of 2.5 μg) or
once-daily HandiHaler 18 μg. Primary outcomes were time to death from
any cause and time to ﬁrst COPD exacerbation. Secondary outcomes
included time to severe (hospitalised) exacerbations and time to major
adverse cardiovascular events (MACE). The study design has been
described previously.11,15
Study population
Patients had a diagnosis of COPD with forced expiratory volume in 1 s
(FEV1)⩽ 70% of forced vital capacity, FEV1⩽ 70% predicted and ⩾ 10 pack-
years of smoking history, were aged ⩾ 40 years and were permitted to use
their usual background treatment for COPD other than anticholinergics. All
patients (including those with premature discontinuation) were followed
up for vital status until the end of the study.
At enrolment, patients were asked to provide details of COPD and other
medication received within the past 2 months. For this post hoc subgroup
analysis, patients were included if they were not receiving short- or long-
acting inhaled anticholinergics during the 2 months before the start of
the trial.
Statistical analysis
Hazard ratios (HR) and 95% conﬁdence intervals (CI) were calculated using
a Cox-proportional hazards regression model (without covariate adjust-
ment). Rate ratios and 95% CI were used to compare incidence rates.
Negative binomial regression models were used to compare event rates.
For analysis of death (including fatal MACE), events occurring during
treatment and vital status follow-up (vital status analysis) were considered.
For all other analyses (including MACE and COPD exacerbations), only
events with onset in the on-treatment period were noted (on-treatment
analysis). An on-treatment sensitivity analysis was conducted for time to
death. Subgroup analyses by patient characteristics at baseline were
conducted for time to death and exacerbation risk.
RESULTS
Study population
Overall, 6,966 patients naive to anticholinergic treatment at
baseline (Respimat 2.5 μg n= 2,345; Respimat 5 μg n= 2,312;
HandiHaler 18 μg n= 2,309) were randomised and treated for a
mean follow-up duration of 834 days. A total of 541 (23.1%), 517
(22.4%) and 500 (21.7%) patients in the Respimat 2.5 μg, 5 μg and
HandiHaler 18 μg groups, respectively, prematurely discontinued
from the study. Discontinuation attributed to anticholinergic side
effects occurred in 0.7 and 1.0% of patients in the Respimat 2.5
and 5 μg groups, respectively, and 0.9% of patients in the
HandiHaler group.
Patient baseline demographics and characteristics were similar
in the three groups (Table 1). Most patients were Global Initiative
for Chronic Obstructive Lung Disease (GOLD) stages II (48.8%) and
III (38.4%). The majority of patients (77.3%) were receiving
pulmonary medication at baseline; approximately half of the
patients were taking an inhaled corticosteroid or long-acting
β2-agonist (50.2 and 51.6%, respectively) (Table 1). Of the patients
who reported symptoms of breathlessness (n= 6,688; 96.1%), the
majority were classiﬁed as modiﬁed Medical Research Council
(mMRC) scale 1 (n= 2,694, 40.3%) or scale 2 (n= 2,486, 37.2%)
(Table 1). Approximately 8–9% of patients had a history of cardiac
arrhythmia (Table 1). A total of 3,349 (48.1%) patients had ⩾ 1
COPD exacerbation in the year before the study (Table 1).
Safety
Risks of death (measured as time to death, vital status analysis)
and the adjudicated causes of death were similar between
both doses of Respimat and HandiHaler 18 μg (Figures 1a, b;
Table 2). Similar results were obtained for an on-treatment
sensitivity analysis of time to fatal adverse event (Respimat
2.5 μg versus Respimat 5.0 μg: HR (95% CI) 1.21 (0.95, 1.54);
Respimat 2.5 μg versus HandiHaler 18 μg: HR (95% CI) 1.11 (0.87,
1.40); Respimat 5 μg versus HandiHaler 18 μg: 0.91 (0.71, 1.17)).
Subgroup analyses (including cardiac history at baseline and
pulmonary comedication at baseline) showed no difference
between groups.
Risk of ﬁrst MACE (on-treatment analysis) was similar for
Respimat 2.5 μg and 5.0 μg versus HandiHaler 18 μg (HR (95% CI):
1.11 (0.81, 1.51) P=0.523, and HR (95% CI) 1.20 (0.88, 1.63) P=0.244,
Table 1. Patient disposition and baseline characteristics in
anticholinergic-naive patients
Variable Tiotropium
Respimat
2.5 μg
(n= 2,344)
Tiotropium
Respimat
5 μg
(n= 2,309)
Tiotropium
HandiHaler
18 μg
(n= 2,307)
Gender, n (%)
Male 1,686 (71.9) 1,694 (73.4) 1,641 (71.1)
Mean age, years (s.d.) 64.1 (9.3) 64.0 (9.2) 64.1 (9.2)
BMI, mean kg/m2 (s.d.) 26.1 (5.7) 26.0 (5.7) 26.1 (5.8)
Smoking history, mean
pack-years (s.d.)
42.2 (24.3) 42.5 (23.9) 41.6 (23.6)
Post-bronchodilator spirometry, mean (s.d.)
FEV1, L 1.365 (0.495) 1.374 (0.494) 1.360 (0.488)
FEV1, % predicted 48.7 (14.1) 48.8 (13.9) 48.8 (14.2)
FVC, L 2.688 (0.835) 2.711 (0.840) 2.685 (0.846)
Ratio of FEV1 to FVC 0.512 (0.116) 0.511 (0.114) 0.511 (0.113)
GOLD stage, n (%)
I 4 (0.2) 10 (0.4) 7 (0.3)
II 1,142 (48.7) 1,112 (48.2) 1,140 (49.4)
III 896 (38.2) 908 (39.3) 868 (37.6)
IV 261 (11.1) 238 (10.3) 263 (11.4)
mMRC score, n (%)
0 (including not breathless) 186 (8.0) 200 (8.7) 216 (9.4)
1 923 (39.5) 871 (37.8) 900 (39.1)
2 841 (36.0) 832 (36.1) 813 (35.3)
3 350 (15.0) 370 (16.1) 331 (14.4)
4 38 (1.6) 32 (1.4) 42 (1.8)
Patients with exacerbations in the previous year, n (%)
0 1,210 (51.6) 1,203 (52.1) 1,191 (51.6)
1 654 (27.9) 653 (28.3) 666 (28.9)
⩾ 2 477 (20.3) 451 (19.5) 448 (19.4)
Previous cardiac
arrhythmia, n (%)
208 (8.9) 212 (9.2) 194 (8.4)
Previous MI, n (%) 118 (5.0) 122 (5.3) 117 (5.1)
Previous stroke, n (%) 53 (2.3) 56 (2.4) 46 (2.0)
Previous IHD or CAD, n (%) 346 (14.8) 334 (14.5) 333 (14.4)
Taking CV medication, n (%) 1,109 (47.3) 1,062 (46.0) 1,061 (46.0)
Use of respiratory
medication, n (%)
1,830 (78.1) 1,764 (76.4) 1,785 (77.4)
LABA 1,195 (51.0) 1,177 (51.0) 1,219 (52.8)
SABA 1,076 (45.9) 1,061 (46.0) 1,052 (45.6)
ICS 1,167 (49.8) 1,152 (49.9) 1,175 (50.9)
Abbreviations: BMI, body mass index; CAD, coronary artery disease; CV,
cardiovascular; FEV1, forced expiratory volume in 1 s; FVC, forced vital
capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease; ICS,
inhaled corticosteroid; IHD, ischaemic heart disease; LABA, long-acting
β2-agonist; MI, myocardial infarction; mMRC, modiﬁed Medical Research
Council; SABA, short-acting β2-agonist; s.d, standard deviation.
Six patients (Respimat 2.5 μg, one patient; Respimat 5 μg, three patients;
HandiHaler 18 μg, two patients) from sites with data irregularities were
excluded.
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respectively; Figure 1c). Rates of fatal MACE (vital status analysis)
were similar in each of the treatment groups (Figure 1d; Table 2).
Efﬁcacy
Risk of exacerbation (measured as time to ﬁrst exacerbation,
on-treatment analysis) showed no signiﬁcant difference
between the Respimat groups and HandiHaler 18 μg (Figure 2a;
Table 3). The risk of moderate-to-severe and severe (hospitalised)
exacerbations was also similar across groups (Figure 2b;
Table 3).
Exacerbation risk did not differ between treatments in any of
the patient subgroups. Patients with less impaired lung function
Figure 1. Kaplan–Meier plots showing time to (a) death, (b) FAE, (c) ﬁrst MACE and (d) fatal MACE. Data for patients with event are n (%). CI,
conﬁdence interval; COPD, chronic obstructive pulmonary disease; FAE, fatal adverse event; MACE, major adverse cardiovascular event. Six
patients (Respimat 2.5 μg, one patient; Respimat 5 μg, three patients; HandiHaler 18 μg, two patients) from sites with data irregularities were
excluded from ﬁrst MACE analyses. On-treatment analyses (from randomisation to drug stop+30 days).
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(GOLD stage II) responded equally to Respimat and HandiHaler
with respect to the rate of any exacerbation, moderate-to-severe
exacerbations and severe exacerbations (Table 3). As might be
expected, patients in the GOLD stage II category experienced
fewer exacerbations than the overall population of
anticholinergic-naive patients (Table 3).
DISCUSSION
Main ﬁndings
The present study showed that patients with COPD who were
naive to anticholinergic treatment at baseline, and who were
treated with Respimat 2.5 or 5 μg, were at a similar risk of mortality
and adverse cardiac events as patients receiving HandiHaler 18 μg.
Table 2. Incidence of adjudicated causes of mortality and fatal MACE in anticholinergic-naive patients
Variable Tiotropium
Respimat
2.5 μg
(n= 2,345)
Tiotropium
Respimat
5 μg
(n=2,312)
Tiotropium
HandiHaler
18 μg
(n=2,309)
Rate ratio (95% CI)
Tiotropium Respimat
2.5 μg vs. HandiHaler
Tiotropium Respimat
5 μg vs. HandiHaler
Total patients with deaths 169 (3.2) 149 (2.8) 159 (3.0) 1.05 (0.84, 1.30) 0.93 (0.75, 1.17)
Patients with fatal MACE 49 (0.9) 49 (0.9) 43 (0.8) 1.12 (0.75, 1.69) 1.14 (0.75, 1.71)
Adjudicated causes of death
Cardiac disorders 10 (0.2) 13 (0.2) 5 (0.1) 1.97 (0.67, 5.77) 2.59 (0.92, 7.27)
General disorders including sudden
(cardiac) death
53 (1.0) 41 (0.8) 46 (0.9) 1.14 (0.77, 1.69) 0.89 (0.58, 1.35)
Neoplasms benign, malignant and
unspeciﬁed
44 (0.8) 29 (0.5) 32 (0.6) 1.36 (0.86, 2.14) 0.90 (0.55, 1.49)
Respiratory, thoracic and mediastinal
disorders
36 (0.7) 34 (0.6) 36 (0.7) 0.99 (0.62, 1.57) 0.94 (0.59, 1.50)
COPD (PT) 34 (0.6) 31 (0.6) 34 (0.6) 0.99 (0.61, 1.59) 0.91 (0.56, 1.48)
Infections and infestations 10 (0.2) 10 (0.2) 13 (0.2) 0.76 (0.33, 1.73) 0.77 (0.34, 1.75)
Gastrointestinal disorders 3 (0.1) 9 (0.2) 8 (0.2) 0.37 (0.10, 1.39) 1.12 (0.43, 2.91)
Abbreviations: CI, conﬁdence interval; COPD, chronic obstructive pulmonary disease; MACE, major adverse cardiovascular event; MedDRA, Medical Dictionary
for Regulatory Activities; PT, preferred term; SOC, system organ class. Data shown are n (rate per 100 patient-years). Risk-adjusted rates of adjudicated causes
of death by treatment, MedDRA (version 16.0, MedDRA MSSO, McLean, VA, USA) SOC and PT. Vital status analysis. MACE included stroke, myocardial infarction,
sudden death, cardiac death, sudden cardiac death or fatal event in the SOCs for cardiac and vascular disorders.
Figure 2. Kaplan–Meier plots showing time to (a) ﬁrst exacerbation, and (b) ﬁrst severe (hospitalised) exacerbation. Data for patients with
event are n (%). COPD exacerbations were deﬁned as the worsening of two or more major respiratory symptoms (dyspnoea, cough, sputum,
chest tightness or wheezing) with a duration of at least 3 days requiring speciﬁed treatment changes: (a) mild exacerbations: a newly
prescribed maintenance bronchodilator; (b) moderate exacerbations: a prescription for antibiotics, systemic glucocorticoids or both; (c) severe
exacerbations: hospitalisation. Abbreviations: CI, conﬁdence interval; COPD, chronic obstructive pulmonary disease. Six patients (Respimat
2.5 μg, one patient; Respimat 5 μg, three patients; HandiHaler 18 μg, two patients) from sites with data irregularities were excluded from
analyses. On-treatment analyses (from randomisation to drug stop+1 day).
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Compared with the overall population, the present patient
subgroup was similar to the TIOSPIR primary study population
with regards to baseline characteristics; however, mortality rates
during the study were slightly lower. It is likely that patients who
were anticholinergic naive at baseline had less severe disease than
the overall population; indeed, a slightly higher percentage of
patients was classiﬁed as GOLD stage II. In addition, patients in the
anticholinergic-naive subgroup were receiving fewer cardiovas-
cular medications at baseline, indicating fewer cardiovascular
comorbidities. Together, this may have contributed to the lower
mortality rates observed. Nevertheless, the results of this post hoc
analysis of TIOSPIR were consistent with the main study ﬁndings.
In addition, the analysis addresses concerns that the safety of
tiotropium Respimat could not be completely demonstrated in
TIOSPIR because of a potentially selected population with a higher
tolerance to anticholinergic effects at baseline.
Interpretation of ﬁndings in relation to previously published work
COPD is a heterogeneous disease comprising a wide range of
clinical phenotypes that may respond differently to treatment.16
Not all of these phenotypes (particularly patients with mild COPD)
are represented within populations included in RCTs. Indeed, a
common criticism of evidence-based medicine is that it is not
known how well RCT evidence applies to COPD patients typically
seen within clinical practice.12–14
In a comparison of primary care data from the Uncovering and
Noting Long-term Outcomes in COPD (UNLOCK) database with six
large RCTs of patients with COPD, signiﬁcant differences were
observed with respect to baseline characteristics.13 Patients
included in the RCTs tended to be younger, were predominantly
male and had signiﬁcantly worse lung function and quality-of-life
scores than primary care patients. Disparities were also observed
with respect to exacerbations: a lower mean exacerbation rate per
year and lower number of patients with ⩾ 1 or ⩾ 2 exacerbations
Table 3. Risk of exacerbation in anticholinergic-naive patients
Variable Tiotropium
Respimat
2.5 μg
(n= 2,344)
Tiotropium
Respimat
5 μg
(n=2,309)
Tiotropium
HandiHaler
18 μg
(n= 2,307)
Hazard ratio (95% CI); P-value
Tiotropium Respimat
2.5 μg versus
HandiHaler
Tiotropium Respimat
5 μg versus
HandiHaler
All patients
Any exacerbation
Patients with event, n (%) 979 (41.8) 923 (40.0) 948 (41.1) 1.04 (0.95, 1.14);
P= 0.359
0.99 (0.90, 1.08);
P= 0.829
No. of events 2,022 2,002 1,955
Adjusted rate of events/patient-year
(95% CI)
0.45 (0.42, 0.48) 0.45 (0.42, 0.48) 0.44 (0.41, 0.47)
Moderate-to-severe exacerbation
Patients with event, n (%) 957 (40.8) 902 (39.1) 926 (40.1) 1.04 (0.95, 1.14);
P= 0.364
0.99 (0.90, 1.09);
P= 0.840
No. of events 1,968 1,956 1,902
Adjusted rate of events/patient-year
(95% CI)
0.43 (0.40, 0.47) 0.44 (0.41, 0.47) 0.43 (0.40, 0.46)
Severe (hospitalised) exacerbations
Patients with event, n (%) 282 (12.0) 250 (10.8) 255 (11.1) 1.10 (0.93, 1.30);
P= 0.277
0.99 (0.83, 1.18);
P= 0.917
No. of events 406 376 363
Adjusted rate of events/patient-year
(95% CI)
0.09 (0.08, 0.11) 0.09 (0.08, 0.10) 0.08 (0.07, 0.10)
GOLD stage II subgroup
Any exacerbation
Patients with event, n (%) 442 (38.6) 391 (34.8) 426 (37.1) 1.05 (0.92, 1.20);
P= 0.472
0.95 (0.82, 1.08);
P= 0.422
No. of events 851 809 837
Adjusted rate of events/patient-year
(95% CI)
0.38 (0.34, 0.42) 0.37 (0.34, 0.42) 0.38 (0.34, 0.42)
Moderate-to-severe exacerbation
Patients with event, n (%) 428 (37.3) 380 (33.9) 415 (36.2) 1.04 (0.91, 1.19);
P= 0.546
0.94 (0.82, 1.08);
P= 0.410
No. of events 822 781 817
Adjusted rate of events/patient-year
(95% CI)
0.36 (0.33, 0.40) 0.36 (0.32, 0.40) 0.37 (0.33, 0.41)
Severe (hospitalised) exacerbations
Patients with event, n (%) 84 (7.3) 61 (5.4) 78 (6.8) 1.07 (0.79, 1.46);
P= 0.650
0.81 (0.58, 1.13);
P= 0.206
No. of events 116 84 113
Adjusted rate of events/patient-year
(95% CI)
0.05 (0.04, 0.07) 0.04 (0.03, 0.05) 0.05 (0.04, 0.07)
Abbreviations: CI, conﬁdence interval; GOLD, Global Initiative for Chronic Obstructive Lung Disease.
On-treatment analysis (from randomisation to drug stop+1 day). Six patients (Respimat 2.5 μg, one patient; Respimat 5 μg, three patients; HandiHaler 18 μg,
two patients) from sites with data irregularities were excluded.
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being observed in the UNLOCK population.13 A further interesting
observation from the UNLOCK analysis is that patients with GOLD
stage I or II COPD comprised 20.7% and 53.3%, respectively, of the
total UNLOCK population.13 This compares with a complete
absence of patients at GOLD stage I and 45% of patients at GOLD
stage II in the combined RCTs, normally caused by exclusion
criteria for mild patients. In the TIOSPIR anticholinergic-naive
subpopulation, 0.3% patients were at GOLD stage I (because of
the inclusion of patients with an FEV1 percent predicted of
o70%) and 48.8% patients were at GOLD stage II. Thus, almost
half of the patients in this subgroup were considered to have
moderate COPD. Comparison of other baseline characteristics
from the TIOSPIR anticholinergic-naive subpopulation with those
from the UNLOCK cohort and combined RCTs indicate that this
subgroup may have greater similarity to the UNLOCK population
than other large COPD trials. Fewer patients in the anticholinergic
subgroup had also experienced one or more exacerbation in the
year before the study (48%) than patients from other large RCTs
(59%), thus better reﬂecting the UNLOCK population (44%;
Supplementary Table 1). Together, these comparisons indicate
that the anticholinergic-naive subgroup from TIOSPIR may better
reﬂect patients observed in primary care than patients typically
randomised to other large COPD trials.
The primary efﬁcacy outcome from TIOSPIR was time to ﬁrst
COPD exacerbation. Exacerbations are an important component of
COPD, having a signiﬁcant impact on disease progression and
health status, as well as increasing the risk of further exacerbations
and death.17–19 Thus, the prevention of exacerbations is a primary
goal in COPD management.20 Tiotropium Respimat and Handi-
Haler have been shown to reduce COPD exacerbations versus
placebo and other therapies, including among subgroups of
patients.6,21–28 For example, in a prespeciﬁed secondary analysis
of the Understanding Potential Long-term Impacts on Function
with Tiotropium (UPLIFT) trial, tiotropium HandiHaler reduced the
number of exacerbations per patient-year by 16% versus control
in patients naive to maintenance therapy before the study.25 In
subgroup analyses of the Prevention Of Exacerbations with
Tiotropium in COPD (POET-COPD) study, tiotropium HandiHaler
signiﬁcantly prolonged the time to ﬁrst exacerbation (HR (95% CI),
0.88 (0.79, 0.99); P= 0.028) and ﬁrst severe exacerbation (HR (95%
CI), 0.66 (0.48, 0.91); P= 0.012) in GOLD stage II patients, and
signiﬁcantly reduced the annual exacerbation rate (rate ratio [95%
CI], 0.77 (0.63, 0.94); P= 0.012) in maintenance therapy–naive
patients, when compared with salmeterol.27 Before TIOSPIR, the
relative efﬁcacy of exacerbation reduction by Respimat and
HandiHaler was unknown. In this current post hoc analysis, the
incidence of exacerbations was shown to be similar among
anticholinergic-naive patients who were treated with either
Respimat or HandiHaler. Furthermore, the subgroup analysis of
exacerbation risk in GOLD stage II patients shows that Respimat
and HandiHaler have similar efﬁcacy proﬁles in patients with less
impaired lung function or health status.
Further evidence for tiotropium’s safety was provided by the
low incidence of discontinuations observed in each of the
treatment groups because of anticholinergic side effects. Other
clinical studies of tiotropium in COPD have reported similarly low
rates of discontinuation because of undesirable effects such as dry
mouth, occurring in 0.1% of patients treated with tiotropium
Respimat 5 μg (5 clinical trials)2 and 0.2% of patients treated with
tiotropium HandiHaler 18 μg (28 clinical trials).1
Strengths and limitations of this study
A key limitation of the study is that it was a post hoc analysis rather
than a prespeciﬁed subgroup analysis. Nevertheless, being one of
the largest, long-term, randomised trials of a broad range of
patients with COPD, TIOSPIR lends itself to statistically powerful
subgroup analyses.
Implications for future research, policy and practice
This post hoc analysis examined whether the subpopulation of
patients in TIOSPIR who were naive to anticholinergic therapy at
baseline responded differently to treatment with tiotropium
Respimat than to tiotropium HandiHaler. Patients who are naive
to anticholinergic therapy are frequently seen within daily
practice, and the results of this analysis will therefore be of
particular interest to primary care physicians and policy makers.
Better deﬁnition of treatment responses of individuals according
to their treatment history will ultimately help tailor more targeted
interventions in patients with COPD.
Conclusions
In this post hoc analysis, patients with COPD who were naive to
anticholinergic treatment had similar efﬁcacy and safety proﬁles
when treated with tiotropium Respimat or HandiHaler in the
TIOSPIR trial.
This study provides further data that addresses prior safety
concerns regarding tiotropium Respimat and provides additional
evidence that tiotropium Respimat treatment is also safe for
patients who were not previously treated with an anticholinergic,
including patients with mild disease more commonly seen in
primary care.
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